CHEMOMAB THERAPEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.68 USD | +6.27% |
|
+3.05% | +33.33% |
| Apr. 10 | Transcript : Chemomab Therapeutics Ltd. - Special Call | |
| Mar. 07 | Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Calendar
2024-05-09
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.68
USD
Average target price
7
USD
Spread / Average Target
+929.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.33% | 9.66M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.72% | 22.18B | |
| -16.67% | 21.2B | |
| -8.54% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- CMMB Stock
- News Chemomab Therapeutics Ltd.
- Oppenheimer Downgrades Chemomab Therapeutics to Perform From Outperform, Removes $7 Price Target
